Drug
Leucovorin clinical trials
Also written Folinic acid, Wellcovorin, Lederfolin and NSC-3590.
Keep track of what changes. Save the Leucovorin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Other names
- Folinic acid
- 101
Studies by the year they started
347 studies that test it; most in 2018 (23); 1 more planned to start later
| Year | Studies |
|---|---|
| 1992 | 2 |
| 1993 | 2 |
| 1994 | 5 |
| 1995 | 2 |
| 1996 | 4 |
| 1997 | 4 |
| 1998 | 2 |
| 1999 | 5 |
| 2000 | 8 |
| 2001 | 4 |
| 2002 | 10 |
| 2003 | 11 |
| 2004 | 12 |
| 2005 | 11 |
| 2006 | 16 |
| 2007 | 6 |
| 2008 | 3 |
| 2009 | 16 |
| 2010 | 11 |
| 2011 | 18 |
| 2012 | 16 |
| 2013 | 8 |
| 2014 | 10 |
| 2015 | 13 |
| 2016 | 10 |
| 2017 | 18 |
| 2018 | 23 |
| 2019 | 15 |
| 2020 | 15 |
| 2021 | 12 |
| 2022 | 7 |
| 2023 | 11 |
| 2024 | 12 |
| 2025 | 14 |
| 2026 | 11 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 65 · Other 286
ImmunityBio, Inc. (18) · National Cancer Institute (NCI) (13) · M.D. Anderson Cancer Center (11) · National Health Research Institutes, Taiwan (10) · Children's Oncology Group (9) · Fujian Cancer Hospital (8) · University of Miami (7) · SWOG Cancer Research Network (6)
Often tested with
Tested in the same studies.
Fluorouracil (263) · Oxaliplatin (176) · Irinotecan (79) · Capecitabine (50) · Paclitaxel (47) · Bevacizumab (44) · Docetaxel (43) · Cisplatin (40)
Studies
Open first, then newest update. How each study uses Leucovorin is read from its arms, and is right about nine times in ten.
Testing it · 351
- Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel CancersRecruitingPhase 2SWOG Cancer Research NetworkNCT04205968Written as Leucovorin
- Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)RecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT03109288Written as Leucovorin
- A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal AdenocarcinomaRecruitingPhase 2AstraZenecaNCT07069712Written as FLOT Chemotherapy
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377Written as Leucovorin
- A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib StudiesRecruitingPhase 2Mirati Therapeutics Inc.NCT07415031Written as Leucovorin
- NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal CancerRecruitingPhase 1M.D. Anderson Cancer CenterNCT04615013Written as Leucovorin
- DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic CancerRecruitingPhase 1/2Ohio State University Comprehensive Cancer CenterNCT07705919Written as Leucovorin Calcium
- Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2Mayo ClinicNCT06078709Written as Leucovorin Calcium
- Pan Tumor Rollover StudyRecruitingPhase 2Bristol-Myers SquibbNCT03899155Written as Leucovorin
- NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar TrialRecruitingPhase 2Roswell Park Cancer InstituteNCT06821997Written as Leucovorin Calcium
- Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract CancerRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07831993Written as Leucovorin
- A Prospective, Open-Label, Randomized Controlled Clinical Study Comparing Hepatic Arterial Infusion Chemotherapy (HAIC) With Capecitabine as Adjuvant Therapy After Radical Surgery for Malignant Biliary Tract TumorsRecruitingPhase 4Zhai WenlongNCT07790445Written as Oxaliplatin + 5-Fluorouracil/Leucovorin
- Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal CancerNot yet recruitingPhase 1City of Hope Medical CenterNCT07363408Written as Leucovorin Calcium
- Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract CancerRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07797816Written as Leucovorin
- PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric CancerRecruitingPhase 1City of Hope Medical CenterNCT04329494Written as Leucovorin
- mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-lineRecruitingPhase 2Seoul National University Bundang HospitalNCT07062536Written as Oxaliplatin, 5FU, leucovorin
- SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC TrialNot yet recruitingPhase 2Northwestern UniversityNCT07748611Written as Leucovorin
- Study of NALIRIFOX in Advanced Unresectable Small Bowel TumorsRecruitingPhase 2Tiago Biachi de CastriaNCT06835387Written as Leucovorin
- Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal CancerRecruitingPhase 3Canadian Cancer Trials GroupNCT06205485Written as Leucovorin
- Phase Ib/IIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) AdenocarcinomaNot yet recruitingPhase 1/2Kaohsiung Medical University Chung-Ho Memorial HospitalNCT07680569Written as Oxaliplatin + 5-Fluorouracil/Leucovorin
See all 351 studies that test Leucovorin →
Given in every arm · 539 — Leucovorin is usual care beside what is tested
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2National Cancer Institute (NCI)NCT06124157Written as Leucovorin
- A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric CancerRecruitingPhase 3Astellas Pharma Global Development, Inc.NCT07673887Written as Folinic acid
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT06317662Written as Leucovorin
- A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerRecruitingPhase 3Astellas Pharma Global Development, Inc.NCT06901531Written as Folinic acid (leucovorin or local equivalent)
- The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical TrialsRecruitingPhase 4PfizerNCT05203172Written as Leucovorin
- A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal CancerRecruitingPhase 2AbbVieNCT06820463Written as Leucovorin
- A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.Not yet recruitingPhase 3AstraZenecaNCT07877818Written as FLOT Chemotherapy
- Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06780111Written as Leucovorin
- A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United StatesRecruitingPhase 2BeOne MedicinesNCT07554521Written as Leucovorin
- A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C MutationNot yet recruitingPhase 2Eli Lilly and CompanyNCT07814417Written as Leucovorin/levofolinate calcium
- A Study of ASP3082 in Adults With Advanced Solid TumorsRecruitingPhase 1Astellas Pharma IncNCT05382559Written as Leucovorin
- A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 3BeOne MedicinesNCT07043400Written as Leucovorin
- A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCCRecruitingPhase 2BeOne MedicinesNCT07733180Written as Leucovorin
- Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More TreatmentNot yet recruitingPhase 2SWOG Cancer Research NetworkNCT07636564Written as Leucovorin Calcium
- Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )RecruitingPhase 3Revolution Medicines, Inc.NCT07621718Written as Leucovorin (Calcium Folinate)
- Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)RecruitingPhase 3GenmabNCT07775287Written as Leucovorin (Calcium Folinate)
- Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06469944Written as Leucovorin
- A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)RecruitingPhase 1Merck Sharp & Dohme LLCNCT05067283Written as leucovorin
- A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06997497Written as Leucovorin/levofolinate calcium
- A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS MutationRecruitingPhase 1/2Genfleet Therapeutics (Shanghai) Inc.NCT07678593Written as Leucovorin
Showing 20 of 539.
As the comparator · 49 — what is tested is compared with Leucovorin
- FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)Not yet recruitingPhase 2Sun Yat-sen UniversityNCT07621497Written as Calcium Folinate
- Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2RecruitingPhase 3AstraZenecaNCT07431281Written as Leucovorin
- A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal CancerRecruitingPhase 1/2Janssen Research & Development, LLCNCT05379595Written as Leucovorin
- Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.RecruitingPhase 3Gruppo Oncologico del Nord-OvestNCT06897644Written as Leucovorin
- A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic ChemotherapyNot yet recruitingPhase 3MediLink Therapeutics (Suzhou) Co., Ltd.NCT07803783Written as Leucovorin
- Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic CancerRecruitingPhase 3NRG OncologyNCT06958328Written as Leucovorin Calcium
- A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine CarcinomaNot yet recruitingPhase 3Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07595913Written as 5-fluorouracil, Calcium folinate and Irinotecan
- Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon CancerRecruitingPhase 3AkesoNCT07412613Written as Calcium Folinate
- Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or MutationsNot yet recruitingPhase 3TransThera Sciences (Nanjing), Inc.NCT07328919Written as Oxaliplatin, fluorouracil, calcium folinate, irinotecan, capecitabine
- Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LVRecruitingPhase 1/2Dai, GuanghaiNCT06782685Written as LV
- HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic CancerNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT06383078Written as Folinic acid
- NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic CancerRecruitingPhase 2Seoul National University HospitalNCT04371224Written as Leucovorin
- A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine CarcinomaRecruitingPhase 3Hutchison Medipharma LimitedNCT05015621Written as 5-fluorouracil, Calcium folinate and Irinotecan
- A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)Active, not recruitingPhase 3Bristol-Myers SquibbNCT04008030Written as Leucovorin
- Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and AdolescentsActive, not recruitingPhase 3Dana-Farber Cancer InstituteNCT03020030Written as LEUCOVORIN CALCIUM
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaCompletedPhase 3National Cancer Institute (NCI)NCT00408005Written as Leucovorin Calcium
- Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Active, not recruitingPhase 3Revolution Medicines, Inc.NCT06625320Written as leucovorin
- Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT05239741Written as Leucovorin
- Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingPhase 2ImmunityBio, Inc.NCT04390399Written as Leucovorin
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)CompletedPhase 1/2Hoffmann-La RocheNCT03193190Written as Leucovorin
Showing 20 of 49.
Codes
What other systems call Leucovorin · ClinicalTrials.gg INT007224
- MeSH (NLM) D002955LeucovorinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) Q573I9DVLPLEUCOVORINConfirmed FDA, NLM
- RxNorm 6313One source FDA
- NCI Thesaurus C71631LeucovorinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D002955 | Leucovorin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | Q573I9DVLP | LEUCOVORIN | Confirmed FDA, NLM |
| RxNorm | 6313 | — | One source FDA |
| NCI Thesaurus | C71631 | Leucovorin | One source FDA |
Also registered as leucovorin calcium (UNII RPR1R4C0P4 · RxNorm 225852) and leucovorin calcium pentahydrate (UNII R3W57OBQ5W).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.